̽»¨¾«Ñ¡

Hanna Dahlstrand

Hanna Dahlstrand

Affiliated to Research | Docent
Visiting address: BioClinicum, Visionsgatan 4, J6, 17164 Solna
Postal address: K7 Onkologi-Patologi, K7 Forskning Holmgren Dahlstrand, 171 77 Stockholm
Part of:

About me

  • Hanna Dahlstrand is associate professor in oncology and senior physician in
    oncology and gynecological oncology at Theme Cancer, Karolinska University Hospital. She is research team leader in group Östman, . The research focuses on clinical and translational research in gynecologic cancer.

Selected publications

  • Article: GYNECOLOGIC ONCOLOGY. 2025;193:148-155
    Corvigno S; Fernebro J; Severin-Karisson J; Mezheieusky A; Martin-Bernabe A; Fuente LMDL; Westbom-Fremer S; Carlson JW; Klein C; Kannisto P; Hedenfalk I; Malander S; Ostma A; Dahlstrand H
  • Article: CANCER RESEARCH COMMUNICATIONS. 2024;4(12):3190-3200
    Kjeldsen MK; Jorgensen M; Gronseth DSB; Schonemann-Lund M; Nyvang G-B; Haslund CA; Knudsen AO; Motavaf AK; Malander S; Anttila M; Lindahl G; Maeenpaeae J; Dimoula M; Werner TL; Iversen TZ; Hietanen S; Fokdal L; Dahlstrand H; Bjorge L; Birrer MJ; Mirza MR; Rossing M
  • Article: LANCET. 2024;403(10421):31-43
    Oaknin A; Gladieff L; Martinez-Garcia J; Villacampa G; Takekuma M; De Giorgi U; Lindemann K; Woelber L; Colombo N; Duska L; Leary A; Godoy-Ortiz A; Nishio S; Angelergues A; Rubio MJ; Farinas-Madrid L; Yamaguchi S; Lorusso D; Ray-Coquard I; Manso L; Joly F; Alarcon J; Follana P; Romero I; Lebreton C; Perez-Fidalgo JA; Yunokawa M; Dahlstrand H; D'Hondt V; Randall L

Articles

  • Journal article: ANNALS OF ONCOLOGY. 2024;35:s674
    Hahn L; Irenaeus S; Wenthe J; Eriksson E; Schiza A; Dahlstrand H; Olsson-Stromberg U; Krause J; Sundin A; Sandin LC; Jarblad JL; Liljefors M; Loskog A; Ullenhag GJ
  • Journal article: ANNALS OF ONCOLOGY. 2024;35:s573
    Kjeldsen MK; Gronseth DBS; Nyvang G-B; Haslund CA; Malander S; Anttila MA; Lindahl G; Maenpaa J; Dimoula M; Werner T; Iversen TZ; Hietanen S; Fokdal L; Dahlstrand H; Bjorge L; Rossing M; Mirza MR
  • Article: CANCER CAUSES & CONTROL. 2024;35(8):1101-1109
    Skoeld C; Corvigno S; Dahlstrand H; Enblad G; Mezheyeuski A; Sundstroem-Poromaa I; Stalberg K; Tolf A; Glimelius I; Koliadi A
  • Journal article: CANCER RESEARCH. 2023;83(8_Supplement):ct235
    Hahn A; Irenaeus S; Wenthe J; Eriksson E; Schiza A; Dahlstrand H; Olsson-Strömberg U; Krause J; Sundin A; Sandin L; Jarblad JL; Liljefors MG; Rowinsky E; Loskog A; Ullenhag GJ
  • Article: SEMINARS IN CANCER BIOLOGY. 2022;86(Pt 3):207-223
    Schoutrop E; Moyano-Galceran L; Lheureux S; Mattsson J; Lehti K; Dahlstrand H; Magalhaes I
  • Journal article: CANCER RESEARCH. 2021;81(22_Supplement):po-018-po-018
    Wenthe J; Eriksson E; Sandin L; Lövgren T; Jarblad JL; Dahlstrand H; Olsson-Strömberg U; Schiza A; Sundin A; Irenaeus S; Rowinsky E; Ullenhag G; Loskog A
  • Article: EBIOMEDICINE. 2021;65:103269
    Micke P; Strell C; Mattsson J; Martin-Bernabe A; Brunnstrom H; Huvila J; Sund M; Warnberg F; Ponten F; Glimelius B; Hrynchyk I; Mauchanski S; Khelashvili S; Garcia-Vicien G; Mollevi DG; Edqvist P-H; Reilly AO; Corvigno S; Dahlstrand H; Botling J; Segersten U; Krzyzanowska A; Bjartell A; Elebro J; Heby M; Lundgren S; Hedner C; Borg D; Brandstedt J; Sartor H; Malmstrom P-U; Johansson M; Nodin B; Backman M; Lindskog C; Jirstrom K; Mezheyeuski A
  • Article: ADVANCES IN THERAPY. 2020;37(12):5023-5031
    Magalhaes I; Fernebro J; Abd Own S; Glaessgen D; Corvigno S; Remberger M; Mattsson J; Dahlstrand H
  • Article: GYNECOLOGIC ONCOLOGY. 2020;159(3):860-868
    Corvigno S; Mezheyeuski A; De La Fuente LM; Westbom-Freme S; Carlson JW; Fernebro J; Avall-Lundqvist E; Kannisto P; Hedenfalk I; Malander S; Rolny C; Dahlstrand H; Ostman A
  • Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 2020;125(4):325-329
    Tholander B; Koliadi A; Botling J; Dahlstrand H; Von Heideman A; Ahlström H; Öberg K; Ullenhag GJ
  • Article: PLOS ONE. 2020;15(7):e0236291
    Yang C; Zhang Y; Chen Y; Ragaller F; Liu M; Corvigno S; Dahlstrand H; Carlson J; Chen Z; Nasman A; Waraky A; Lin Y; Larsson O; Haglund F
  • Article: EMBO MOLECULAR MEDICINE. 2020;12(4):e11177
    Moyano-Galceran L; Pietila EA; Turunen SP; Corvigno S; Hjerpe E; Bulanova D; Joneborg U; Alkasalias T; Miki Y; Yashiro M; Chernenko A; Jukonen J; Singh M; Dahlstrand H; Carlson JW; Lehti K
  • Journal article: CLINICAL CANCER RESEARCH. 2019;25(22_Supplement):gmm-041-gmm-041
    Moyano-Galceran L; Turunen SP; Pietilä E; Alkasalias T; Corvigno S; Hjerpe E; Joneborg U; Bulanova D; Eriksson M; Dahlstrand H; Carlson J; Lehti K
  • Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 2018;123(4):225-229
    Halldorsdottir S; Dahlstrand H; Stålberg K
  • Article: NATURE BIOMEDICAL ENGINEERING. 2017;1(10):796-806
    Tanaka N; Kanatani S; Tomer R; Sahlgren C; Kronqvist P; Kaczynska D; Louhivuori L; Kis L; Lindh C; Mitura P; Stepulak A; Corvigno S; Hartman J; Micke P; Mezheyeuski A; Strell C; Carlson JW; Moro CF; Dahlstrand H; Ostman A; Matsumoto K; Wiklund P; Oya M; Miyakawa A; Deisseroth K; Uhlen P
  • Article: JOURNAL OF PATHOLOGY CLINICAL RESEARCH. 2017;3(3):214-224
    Corvigno S; Frodin M; Wisman GBA; Nijman HW; Van der Zee AGJ; Jirstrom K; Nodin B; Hrynchyk I; Edler D; Ragnhammar P; Johansson M; Dahlstrand H; Mezheyeuski A; Ostman A
  • Article: ACTA ONCOLOGICA. 2016;55(12):1467-1476
    Derogar M; Dahlstrand H; Carlsson S; Bjartell A; Hugosson J; Axen E; Johansson E; Lagerkvist M; Nyberg T; Stranne J; Thorsteinsdottir T; Wallerstedt A; Haglind E; Wiklund P; Steineck G
  • Article: LAKARTIDNINGEN. 2016;113:D4WM
    Danielsson A; Dahlstrand H; Edvinsson F; Tranberg M; Wrangsjö A; Fürst C-J
  • Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY. 2016;35(3):256-263
    Nastic D; Kahlin F; Dahlstrand H; Carlson JW
  • Article: ONCOTARGET. 2016;7(14):18573-18584
    Corvigno S; Wisman GBA; Mezheyeuski A; van der Zee AGJ; Nijman HW; Avall-Lundqvist E; Ostman A; Dahlstrand H
  • Show more

All other publications

  • Conference publication: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2022;32:a411
    Fernebro J; Corvigno S; Mezheieusky A; Karlsson JS; La De Fuente LM; Westbom-Fremer SM; Carlson J; Kannisto PM; Hedenfalk IM; Malander SM; Östman A; Dahlstrand H
  • Conference publication: 2020;:a70-a71
    Braicu EI; Pothuri B; Pérez-Fidalgo JA; O’malley D; Honhon B; Graybill W; Fabbro M; Dahlstrand H; Gupta D; Monk BJ
  • Conference publication: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2020;30(Suppl 4):a69-a70
    Dahlstrand H; Pothuri B; Graybill W; de La Motte Rouge T; Mccormick C; Heitz F; Baurain J-F; Yong L; Monk BJ; González-Martin A
  • Preprint: SSRN ELECTRONIC JOURNAL. 2020
    Micke P; Strell C; Matttsson J; Brunnström H; Huvila J; Sund M; Wärnberg F; Ponten F; Glimelius B; Hrynchyk I; Mauchanski S; Khelashvili S; Garcia-Vicién G; Molleví DG; Edqvist P-H; O´Reilly A; Corvigno S; Dahlstrand H; Botling J; Segersten U; Krzyzanowska A; Bjartell A; Elebro J; Heby M; Lundgren S; Hedner C; Borg D; Brändstedt J; Sartor H; Malmström P-U; Johansson M; Nodin B; Backman M; Lindskog C; Jirström K; Mezheyeuski A
  • Conference publication: CLINICAL CANCER RESEARCH. 2019;25(22):104
    Moyano-Galceran L; Turunen SP; Pietila E; Alkasalias T; Corvigno S; Hjerpe E; Joneborg U; Bulanova D; Eriksson M; Dahlstrand H; Carlson J; Lehti K
  • Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e17526
    Dahlstrand H; Corvigno S; Mezheyeuski A; Carlson JW; Fernebro J; Holzlwimmer G
  • Corrigendum: NATURE BIOMEDICAL ENGINEERING. 2018;2(1):48
    Tanaka N; Kanatani S; Tomer R; Sahlgren C; Kronqvist P; Kaczynska D; Louhivuori L; Kis L; Lindh C; Mitura P; Stepulak A; Corvigno S; Hartman J; Micke P; Mezheyeuski A; Strell C; Carlson JW; Moro CF; Dahlstrand H; Ostman A; Matsumoto K; Wiklund P; Oya M; Miyakawa A; Deisseroth K; Uhlen P
  • Conference publication: CANCER RESEARCH. 2016;76:c38
    Corvigno S; Mezheyeuski A; Frodin M; Lindh MB; Guren TK; Pfeiffer P; Kure HE; Ikdahl T; Skovlund E; Tveit KM; Pietras K; Portyanko A; Hrynchyk I; Edler D; Dragomir A; Ponten F; Mulder J; Qvortrup C; Hallstrom M; Ohrling K; Wisman GBA; Avall-Lundqvist E; Johansson M; Harmenberg U; Nijman H; Sandstrom P; Dahlstrand H; Sorbye H; Ginnelius B; Van Der Zee A; Egevad L; Ostman A
  • Meeting abstract: CANCER RESEARCH. 2015;75:1537
    Corvigno S; Wisman B; Van der Zee AGJ; Nijman HW; Mezheyeuski A; Lundkvist EA; Ostman A; Dahlstrand H
  • Book chapter: METHODS OF CANCER DIAGNOSIS, THERAPY, AND PROGNOSIS: METHODS OF CANCER DIAGNOSIS, THERAPY AND PROGNOSIS. 2010;p. 271-283
    Munck-Wikland E; Hammarstedt L; Dahlstrand H
  • Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(15):6004
    Dahlstrand H; Hammarstedt L; Lindquist D; Ye W; Dalianis T; Munck-Wikland E
  • Review: ANTICANCER RESEARCH. 2008;28(2B):1133-1138
    Dahlstrand H; Nasman A; Romanitan M; Lindquist D; Ramqvist T; Dalianis T
  • Review: LAKARTIDNINGEN. 2006;103(44):3366-3368
    Munck-Wikland E; Hammarstedt L; Lindquist D; Romanitan M; Dahlstrand H; Dalianis T
  • Review: LAKARTIDNINGEN. 2006;103(37):2650-2652
    Tegerstedt K; Andreasson K; Dahlstrand H; Ramqvist T; Dalianis T
  • Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2005;93:59-89
    Dahstrand HM; Dalianis T
  • Review: ANTICANCER RESEARCH. 2004;24(3B):1829-1835
    Dahlstrand H; Dahlgren L; Lindquist D; Munck-Wikland E; Dalianis T

Grants

  • The immune system and other cells surrounding the cancer cells in ovarian cancer - how do they affect prognosis and treatment results?
    Swedish Cancer Society
    1 January 2018
    Ovarian cancer is the gynecological cancer that is the highest mortality. A majority of women with ovarian cancer are treated with surgery followed by chemotherapy and, in specific cases, with an anti-vascular antibody, a so-called. angiogenesis inhibitors. Preventing relapse and reducing tumor resistance to cancer treatment is necessary to improve survival in ovarian cancer. Cancer cells are highly dependent on factors in their environment. The tumor microenvironment is the cells and tissue that surround the cancer cells, such as vessels, connective tissue and immunological cells, which are important for the development of the cancer, prognosis and treatment responses. We are researching factors in the tumor microenvironment that can predict responses to angiogenesis inhibitors, or affect the resistance to chemotherapy and survival. This is to avoid giving non-effective treatment. We know today that some immune cells provide better survival in ovarian cancer. The research aims to investigate how the tumor microenvironment interacts with the immune system's cells in tumors to see if there are factors that can strengthen the immune system's work against the cancer. Our studies are conducted both in national and international collaborations. The high mortality and difficulty getting a long-term treatment response in women with spread ovarian cancer means that it is of the utmost importance to clarify markers for prognosis and treatment responses. The goal is to increase survival in the future and extend the tumor-free time for this patient group.
  • The immune system and other cells surrounding the cancer cells in ovarian cancer - how do they affect prognosis and treatment results?
    Swedish Cancer Society
    1 January 2017
    Ovarian cancer is the gynecological cancer that is the highest mortality. A majority of women with ovarian cancer are treated with surgery followed by chemotherapy and, in specific cases, with an anti-vascular antibody, a so-called. angiogenesis inhibitors. Preventing relapse and reducing tumor resistance to cancer treatment is necessary to improve survival in ovarian cancer. Cancer cells are highly dependent on factors in their environment. The tumor microenvironment is the cells and tissue that surround the cancer cells, such as vessels, connective tissue and immunological cells, which are important for the development of the cancer, prognosis and treatment responses. We are researching factors in the tumor microenvironment that can predict responses to angiogenesis inhibitors, or affect the resistance to chemotherapy and survival. This is to avoid giving non-effective treatment. We know today that some immune cells provide better survival in ovarian cancer. The research aims to investigate how the tumor microenvironment interacts with the immune system's cells in tumors to see if there are factors that can strengthen the immune system's work against the cancer. Our studies are conducted both in national and international collaborations. The high mortality and difficulty getting a long-term treatment response in women with spread ovarian cancer means that it is of the utmost importance to clarify markers for prognosis and treatment responses. The goal is to increase survival in the future and extend the tumor-free time for this patient group.
  • Swedish Research Council
    1 January 2015 - 31 December 2017

Employments

  • Affiliated to Research, Department of Oncology-Pathology, ̽»¨¾«Ñ¡, 2024-2026

Degrees and Education

  • Docent, ̽»¨¾«Ñ¡, 2016
  • Doctor Of Philosophy, Department of Oncology-Pathology, ̽»¨¾«Ñ¡, 2002
  • University Medical Degree, ̽»¨¾«Ñ¡, 1999

News from KI

Events from KI